Di'An Diagnostics
The status, timeline and source of this project. A free account opens every field.
Source: International Finance Corporation (IFC)
The proposed investment is a long-term corporate loan of up to US$150 million to Di’An Diagnostics Group Co. Ltd., (“Di’An Diagnostics”, “Di’An”, or the “company”), one of the largest third-party diagnostic services and product providers in China with ~40 laboratories across China serving more than 20,000 medical institutions, and which is publicly listed on the Shenzhen Stock Exchange (300244). U
- Status
- Prospective
- Sector
- Manufacturing (Industrial), Hospital, Government
- Location
- China
- Updated
- 22 Jul 2026
- Source
- International Finance Corporation (IFC)
ConstructChat
Ask ConstructChat about Di'An Diagnostics
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
Sponsoring Agency |
Status
Original status | active |
Taiyo status | Prospective |
Taiyo last update | 2026-07-22 |
Contact
| Not available for this record. |
Description
Description | The proposed investment is a long-term corporate loan of up to US$150 million to Di’An Diagnostics Group Co. Ltd., (“Di’An Diagnostics”, “Di’An”, or the “company”), one of the largest third-party diagnostic services and product providers in China with ~40 laboratories across China serving more than 20,000 medical institutions, and which is publicly listed on the Shenzhen Stock Exchange (300244). Under the proposed use of proceeds, Di’An will: (i) add up to five new diagnostic centers to its independent clinical laboratory (ICL) network including associated cold chain warehouses; (ii) expand existing ICLs including upgrading of equipment; (iii) expand its self-developed In Vitro Diagnostic (IVD) production capacity, (iv) expand its research and development operations; and (v) build advanced IT infrastructure and data analytics functions over the next five years (together, the “Project”). Project locations will mostly be in the major provincial capitals of China. The additional IVD production capacity will mainly focus on advanced diagnostic fields of application, such as mass spectrometry, molecular diagnostics, and micronutrient diagnostics.Di’An Diagnostics Group Co., Ltd. (http://www.dazd.cn/) is located in Hangzhou, Zhejiang, China. Dian Diagnostics Group Co., Ltd. has 9,300 total employees across all of its locations and generated $1.65 billion in sales (USD) by the end of 2020. There are 147 companies in the Dian Diagnostics Group Co., Ltd. corporate family. Most Di’An Diagnostics laboratories and manufacturing facilities are located within industrial parks, with limited exposure to local communities as such parks are typically set up at considerable distances from local residences and sensitive E&S receptor areas. |
Original sector | other |
Location
Country | China |
Source
Source | International Finance Corporation (IFC) |
URL |
More Details
Record type | Project |
Sector | Manufacturing (Industrial), Hospital, Government |
Article published date | 2025-08-08 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
More Manufacturing (Industrial) projects in China
- Yangjiang Nuclear Power Plant Guangdong Province
- Shidao Bay Nuclear Power Plant
- Sanmen Nuclear Power Plant Zhejiang Province
- Baihetan Hydropower Project China
- The Ertan China Hydropower Plant Project
- Yebatan Hydropower Project
- Qinshan Nuclear Power Plant Haiyan County Zhejiang
- Lingao Nuclear Power Station Guangdong
